Safety and Cost-Effectiveness of Early Maternal Newborn Infant Discharge

NCT ID: NCT02372266

Last Updated: 2015-02-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2223 participants

Study Classification

INTERVENTIONAL

Study Start Date

1997-04-30

Study Completion Date

2001-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the effect of a policy of early maternal-newborn infant discharge (12-24 hours) with a home visit on admission to the Level II/III nursery and hospital admissions and readmissions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized controlled trial designed to assess the safety of a policy of early maternal newborn infant discharge compared to a policy of routine discharge 2 to 3 days after delivery. The primary outcome is newborn admissions to the Level II or Level III neonatal care unit or hospital within three days of delivery. Secondary outcomes included admissions and readmissions at 2 weeks, 6 weeks and 6 months following delivery, maternal satisfaction with length of stay and overall birthing experience, lactation continuation rates, maternal anxiety, depression, confidence and family functioning. We applied the American Academy of Pediatrics criteria for early newborn discharge, but planned the analysis by intention to treat.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early Discharge Group

If safety criteria were met, women and infants were discharged home from the hospital at 12 to 24 hours after delivery with a planned home health visit within 48 hours of the discharge.

Group Type EXPERIMENTAL

Early Maternal-Newborn Infant Discharge

Intervention Type OTHER

Discharge from the hospital between 12-24 hours of life

Routine Stay Group

Women and newborns were discharged no sooner than 48 hours after delivery and could stay voluntarily up to 72 hours.

Group Type ACTIVE_COMPARATOR

Routine discharge

Intervention Type OTHER

Discharge of the mother and newborn 2 to 3 days after delivery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Early Maternal-Newborn Infant Discharge

Discharge from the hospital between 12-24 hours of life

Intervention Type OTHER

Routine discharge

Discharge of the mother and newborn 2 to 3 days after delivery

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All pregnant women enrolling for obstetric care at a large military academic health center

Exclusion Criteria

* Planning a move from the area before delivery
* Multiple gestations
* Pre-existing maternal diabetes
* Maternal chronic hypertension
* Maternal age \< 18
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

59th Medical Wing

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

William H. Barth, Jr., M.D., Col(ret), USAF, MC

Chairman, Department of Obstetrics and Gynecology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

William H Barth, MD

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DI950076

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

FWH19960042H

Identifier Type: OTHER

Identifier Source: secondary_id

SGO 96-042

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.